You are here: Home: Audio Program Guide: PCU 2 | 2008 Audio: PCU 2 | 2008
 
 

Go to interview with Anthony Zietman, MD
Go to inteview with Nancy A Dawson, MD

 
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Zietman, MD Anthony Zietman, MD
Jenot and William Shipley
Professor of Radiation Oncology
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts		  
  Click here to download the entire interview  
Track 1 Incidence of prostate cancer and the use of risk stratification to determine need for treatment
Track 2 Active surveillance and clinical indications for withholding treatment
Track 3 ProtecT trial: Evaluating PSA screening and the effectiveness of treatment for clinically localized
prostate cancer
Track 4 Conventional versus escalated doses of radiation therapy
Track 5 Proton beam radiation therapy for the treatment of prostate cancer
Track 6 Morbidity and costs associated with proton beam radiation therapy

Track 7 Metabolic changes secondary to gonadotropin-releasing hormone agonist therapy
Track 8 Surgery versus radiation therapy for patients with high-risk prostate cancer
Track 9 Quality of life in the adjuvant and metastatic settings
Track 10 Management of PSA-only relapse after prostatectomy
Track 11 Development of novel hormonal agents
Track 12 Intermittent versus continuous androgen deprivation

Track 13 Clinical indications for combining androgen deprivation with radiation therapy in practice
     
Dawson, MD Nancy A Dawson, MD
William M Scholl Professor of
Medicine and Oncology
Director, Genitourinary
Oncology Program
Lombardi Comprehensive Cancer
Center at Georgetown University
Washington, DC		  
  Click here to download the entire interview  
Track 1 Case discussion: A 44-year-old man treated on a study for high-risk disease
Track 2 Phase II trial of chemoradiation therapy combined with hormonal therapy in patients with high-risk prostate cancer
Track 3 Clinical trials evaluating docetaxel in prostate cancer
Track 4 Adjuvant chemotherapy for early prostate cancer
Track 5 Tolerability of adjuvant docetaxel
Track 6 Optimal sequencing of chemotherapy and hormonal therapy in the adjuvant setting
Track 7 Docetaxel-related improvement in quality of life for patients with symptomatic metastatic disease
Track 8 Importance of quality of life for patients with metastatic disease
Track 9 Docetaxel-associated side effects
Track 10 Clinical trials of chemotherapy combined with bevacizumab for advanced prostate cancer
Track 11 Bevacizumab-associated side effects

Track 12 Mechanism of action of endothelin receptor antagonists
Track 13 Clinical trial comparing two doses of ZD4054 to placebo for patients with hormone-refractory prostate cancer
Track 14 Effect of bisphosphonates on the bone microenvironment
Track 15 Counseling patients regarding the benefits and risks of hormone therapy
Track 16 Chemotherapy for PSA-only recurrence in clinical practice

Track 17 Complementary therapies for patients with PSA-only disease